

Video Article

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Moo Rim Kang^{1,*}, Glen Yang^{1,*}, Klaus Charisse², Hila Epstein-Barash², Muthiah Manoharan², Long-Cheng Li¹

¹Department of Urology and Helen Diller Comprehensive Cancer Center, University of California, San Francisco

²Alnylam Pharmaceuticals, Inc.

*These authors contributed equally

Correspondence to: Long-Cheng Li at lilc@urology.ucsf.edu

URL: <http://www.jove.com/video/4207/>

DOI: 10.3791/4207

Keywords: Cancer Biology, Issue 65, Medicine, Physiology, bladder tumor, orthotopic, bioluminescent, ultrasound, small RNA,

Date Published: 7/28/2012

Citation: Kang, M.R., Yang, G., Charisse, K., Epstein-Barash, H., Manoharan, M., Li, L.C. An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment. *J. Vis. Exp.* (65), e4207, DOI : 10.3791/4207 (2012).

Abstract

We present a novel method for treating bladder cancer with intravesically delivered small activating RNA (saRNA) in an orthotopic xenograft mouse bladder tumor model. The mouse model is established by urethral catheterization under inhaled general anesthetic. Chemical burn is then introduced to the bladder mucosa using intravesical silver nitrate solution to disrupt the bladder glycosaminoglycan layer and allows cells to attach. Following several washes with sterile water, human bladder cancer KU-7-luc2-GFP cells are instilled through the catheter into the bladder to dwell for 2 hours. Subsequent growth of bladder tumors is confirmed and monitored by *in vivo* bladder ultrasound and bioluminescent imaging. The tumors are then treated intravesically with saRNA formulated in lipid nanoparticles (LNPs). Tumor growth is monitored with ultrasound and bioluminescence. All steps of this procedure are demonstrated in the accompanying video.

Video Link

The video component of this article can be found at <http://www.jove.com/video/4207/>

Protocol

Procedures involving animal subjects have been approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Francisco.

1. Cell Preparation

1. The human bladder cancer cell line KU-7-luc2-GFP (Caliper Life Sciences, Hopkinton, MA) is grown in RPMI-1640 media supplemented with 10% fetal bovine serum and 50 µg/ml gentamicin.
2. Cultures are maintained at 37 °C, 5% CO₂ with media changes every two to three days.
3. Cells were harvested by trypsin digestion and counted using a hemocytometer. A single cell suspension of 2 x 10⁶ cells in 50 µl was prepared in phosphate buffered saline and kept on ice.

2. Orthotopic Bladder Tumor Model

1. Female nude (nu/nu) mice 8-10 weeks old (Simonsen Laboratory, Gilroy, CA) were used.
2. Place a sterile drape over a heating pad to serve as a surgical platform. Sterile lubricating jelly, 24-gauge catheters with stylet needles, silver nitrate solution, and sterile water are prepared.
3. General anesthetic is induced in the mice with inhaled isoflurane (3% for induction, 1-2% for maintenance) and maintained via nosecone. Sterile ophthalmic ointment is applied to the animal's eyes, and a heat pad is used to maintain body heat.
4. Place the mouse in supine position.
5. Gently grasp the animal's vulva with forceps for stabilization.
6. Using a 24-gauge intravenous catheter with the needle stylet removed, the mouse urethra is catheterized. Ample lubrication should be used. With the mouse supine, the urethra is located immediately posterior to the vulvar folds and anterior to the vagina. A 45-degree angle is initially taken in order to cannulate the urethra and pass beneath the pubic bone. A more shallow angle is then taken to pass through the urethra into the bladder. Gentle pelvic pressure to straighten the urethra can often help. Care must be taken to avoid pushing too hard against resistance, as this can lead to urethral or bladder perforation. Urine seen within the catheter confirms its location within the bladder lumen.
7. Aspirate urine from the catheter and bladder lumen using the stylet needle. The stylet needle is used for all subsequent aspirations and injections, leaving the catheter in place. This allows for injection of accurate volumes by eliminating the dead-space within the catheter, and it makes repeated catheterizations unnecessary.
8. To impair the glycosaminoglycan layer of the bladder urothelium, 10 µL of 0.5 M silver nitrate is injected and allowed to dwell for 10 seconds. This may form a white precipitate with remaining urine.
9. Aspirate and discard the precipitate and bladder contents using a stylet needle.

10. Wash the bladder by injecting 100 μ L sterile water. Aspirate and discard the water. Repeat wash with sterile water 3 times for a total of 4 washes.
11. Place a 4-0 silk tie around the urethral meatus to occlude the urethra in preparation for catheter removal.
12. Inject previously prepared 2×10^6 KU-7-luc2-GFP cells in 50 μ L using the stylet needle.
13. Simultaneously remove the catheter and stylet needle, leaving the urethra occluded by the silk tie.
14. The mouse will be maintained under general anesthetic for 2 hours before the silk tie is removed and the animal is awakened.

3. Ultrasound

1. General anesthetic is induced with vaporized isoflurane and maintained via nose cone.
2. A VisualSonics Vevo 770 *In Vivo* High-Resolution Micro-Imaging System (VisualSonics Inc, Toronto, Ontario, Canada) with the RMV-704 40 MHz probe was used.
3. Place the mouse in supine position on the ultrasound platform.
4. Secure the animal's hind legs with tape to avoid excess movement during manipulation of the ultrasound probe.
5. Apply ultrasound gel to the mouse pelvis.
6. Lower a RMV-704 (40 MHz) ultrasound probe onto the mouse pelvis to obtain transverse or longitudinal images.
7. If tumor is found, images can be saved for measurement of tumor dimensions.

4. Bioluminescent Imaging

1. Perform intraperitoneal injection of 200 μ L (150 mg/kg) luciferin substrate.
2. Induce general anesthetic with vaporized isoflurane and maintain via nose cone.
3. Place mice in supine position within the bioluminescence imager.
4. Five minutes after luciferin injection, measure the bioluminescence from the animal in photons per second.

5. saRNA Preparation

1. Synthesize RNA oligonucleotides at a scale of 50-100 μ mol.
2. Anneal complementary single-stranded oligonucleotides into duplex saRNAs.
3. Lipid-nanoparticle (LNP)-saRNA are prepared with the ionizable lipid 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA), distearylphosphatidyl choline, cholesterol, and PEG-DMG using a spontaneous vesicle formation formulation procedure as previously described.¹

6. Intravesical Administration of Formulated saRNA

1. After establishing the orthotopic bladder tumor model, mice are treated with intravesical small activating RNA (saRNA) formulated in lipid nanoparticles (LNPs) (**Table 1**).
2. General anesthetic is established and maintained with vaporized isoflurane, and sterile ophthalmic lubricant is applied.
3. Place the animal in supine position.
4. Perform urethral catheterization as previously described.
5. Place a 4-0 silk tie around the urethra and catheter.
6. Aspirate all urine from the catheter and bladder using an empty syringe and stylet needle.
7. Inject LNP-saRNA intravesically for a total dose of 50 μ L (3 mg/kg). Simultaneously remove the catheter and stylet needle, leaving the urethra occluded by the silk tie.
8. The mouse will remain anesthetized with the urethra occluded for 2 hours.
9. Treatment with intravesical LNP-saRNA was begun on Day 4 after tumor implantation. Mice were treated serially, every 3 days, for a total of 14 treatments.

7. Representative Results

Bladder tumors stemming from KU-7-luc2-GFP cells can be monitored by luciferase bioluminescent imaging (**Figure 1A and C**) and bladder ultrasound (**Figure 1B and D**). Tumors are often detectable within 3-5 days after cell inoculation. We found successful bladder tumor implantation in over 90% of mice. As treatment with intravesical dsRNA ensues, the progression of tumor can be monitored with these modalities. After the animal is sacrificed, tumor growth can also be confirmed using GFP fluorescence. In general, mean bioluminescence correlated with mean ultrasound dimensions for bladder tumors, as seen visually in **Figures 1C and 1D**. However, after animals were sacrificed and tumor was confirmed by GFP, we found that bioluminescence correlated more closely with the presence of viable tumor than did ultrasound measurements. This was especially apparent among mice treated with saRNA (as opposed to controls) because residual scar tissue in treated mice was often visualized by ultrasound but could not be differentiated from live tumor.




Figure 1. Tumor growth kinetics of bladder tumors. (A) Bioluminescence imaging measures the luciferase activity within bladder tumors to confirm their location and growth. (B) *In vivo* bladder ultrasound using a 40MHz probe produces tumor images whose dimensions can be accurately measured. (C) Graphs illustrating the tumor's progressive increase in bioluminescence and ultrasound dimensions. Values represent mean (+/- standard deviation) measurements from 6 animals. [Click here to view larger figure.](#)

Discussion

We present a protocol for the establishment of a mouse orthotopic xenograft bladder tumor model followed by intravesical treatment of the tumors with LNP formulated saRNA that targets the promoter of p21^{CIP1/WAF1} (p21) for transcriptional activation.^{2,3} The resultant tumors can be confirmed and monitored with bioluminescent imaging and bladder ultrasound. Orthotopic models may be superior to intraperitoneal, subcutaneous, or intravenous models by providing a milieu of urine and urothelium that more closely approximates endogenous bladder cancer. A variety of orthotopic mouse bladder tumors have been established using both direct bladder wall injection as well as intravesical instillation.⁴⁻⁸ Intravesical instillation of tumor, as demonstrated here, more closely mimics human bladder tumors which begin superficially in the mucosal epithelium and grow deeper as they progress. Our method of using silver nitrate to accommodate bladders for tumor uptake is inexpensive and technically simple.

Hadaschik *et al.* described intravesical instillation of bladder tumors in mice and reported reliable bioluminescent tumor assessment.⁵ We similarly found high rates of successful tumor implantation with catheterization and cell instillation. Our tumors were not only confirmed with bioluminescence but also with *in vivo* bladder ultrasound, providing an additional method for quantifying tumor progression.

In this protocol, we note several modifications to others' technique. We employed instillation of silver nitrate solution to disrupt the bladder extracellular glycosaminoglycan layer for tumor cell implantation, instead of electrocautery. We found this to be a cheap, simple, and reliable method that minimized potential for user error. During ultrasound evaluation of the bladder, we found it unnecessary to perform urethral catheterization beforehand. As long as the animal had not been subjected to significant distress to cause urination before undergoing anesthesia, the mouse bladder was reliably distended during imaging to allow for excellent tumor visualization. Without a doubt, urethral catheterization was the least reliable step of the protocol. In our experience, catheterization of athymic nude mice is more difficult than in C57 mice. However, with the technique described in this protocol and video, over 90% of animals were repeatedly catheterized successfully for both tumor instillation and treatment.

Disclosures

L.C.L. is a named inventor on pending patent applications related to saRNA which have been filed by the University of California San Francisco and licensed to Alnylam Pharmaceuticals.

Acknowledgements

This research is funded by the AACR Henry Shepard Bladder Cancer Research Grant (09-60-30-LI).

References

1. Semple, S.C., *et al.* Rational design of cationic lipids for siRNA delivery. *Nature biotechnology*. **28**, 172-176 (2010).
2. Li, L.C., *et al.* Small dsRNAs induce transcriptional activation in human cells. *Proceedings of the National Academy of Sciences of the United States of America*. **103**, 17337-17342 (2006).
3. Chen, Z., *et al.* Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells. *Molecular cancer therapeutics*. **7**, 698-703 (2008).
4. Chancellor, M.B., *et al.* Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. *Neurourology and urodynamics*. **19**, 279-287 (2000).
5. Hadaschik, B.A., *et al.* A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. *BJU international*. **100**, 1377-1384 (2007).
6. Fu, C., Apelo, C.A., Torres, B., Thai, K.H., & Hsieh, M.H. Mouse Bladder Wall Injection. *J. Vis. Exp.* (53), e2523, DOI: 10.3791/2523 (2011).
7. Dobek, G.L. & Godbey, W.T. An Orthotopic Model of Murine Bladder Cancer. *J. Vis. Exp.* (48), e2535, DOI: 10.3791/2535 (2011).
8. Dinney, C.P., *et al.* Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. *The Journal of urology*. **154**, 1532-1538 (1995).